The global generator cooling systems market is projected to grow from $3.76 billion in 2026 to $5.03 billion by 2031 at a CAGR of 6.0%. Growth is fueled by rising demand for reliable backup and continuous power in expanding data centers, industrial facilities, and critical infrastructure, especially in the Asia Pacific region. Liquid-cooled and engine-mounted integrated cooling systems dominate the market, with advancements in thermal management and modular solutions enhancing efficiency. Manufacturers focusing on innovation and cost-effective solutions are well positioned to benefit from this expanding market.
The generator cooling systems market is projected to reach USD 5.03 billion by 2031, growing at a CAGR of 6.0%. For readers following Industrials-sector stocks on Pluang, here is the market snapshot as of Oct 23, 2026 19:31 WIB: out of 135 priced stocks, 36 rose and 94 fell. Notable movers include SEB at USD 3,965.96 (+2.65%), GE Aerospace at USD 286.00 (-2.57%) with a typical hold time of 111 days and Pluang order activity skewed 65% Sell / 35% Buy, and Byrna Technologies Inc at USD 4.72 (-2.48%) with 100% sell orders.
AX1 has launched Console 2.0, a platform on the Base blockchain that lets AI agents perform tasks and get paid in USDC using the x402 payment standard by Coinbase. This new version simplifies setup, allowing users to deploy AI agents quickly to work ...
The global computed tomography (CT) market is undergoing significant innovation driven by photon-counting technology, AI integration, mobile imaging, and point-of-care applications. These advancements are enhancing image quality, workflow efficiency,...
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
